CLL survivorship is a concept whose time has come, according to Australian haematologists Dr Pasquale Fedele and Professor Stephen Opat from Monash University.
Writing in the Journal of Clinical Oncology [link here], they said highly effective and less toxic therapies for CLL now meant that most patients will die from non-CLL related causes such as second cancers, vascular disease and infection.
“Many of these conditions and their risk factors can be identified with routine screening and are therefore potentially preventable,” they said.
“Thus, it is likely that further improvement in outcome for our patients with CLL will not come from improvements in CLL-directed therapy, rather from addressing competing causes of death.”
They said a survivorship model of care comprising patient education, surveillance, prevention, early intervention and care coordination was needed to optimise outcomes for patients with CLL.
“Traditional health care models are ill-suited for the provision of survivorship care, with busy practitioners seldom having time to systematically address the complex needs of survivors,” they said.
“A multidisciplinary, survivorship and chronic disease management approach to care in CLL is long overdue.”
They proposed a suite of recommendations across multiple domains of immunity and infections, cardiovascular disease, secondary malignancy, bone disease, frailty, psychological/emotional, social and financial, education and information, and dentition.